J, M., G, R., MT, B., H, S., O, F., L, C., . . . M, S. (2026). Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). International journal of cancer, 158(5), 1396. https://doi.org/10.1002/ijc.70228
Chicago Style (17th ed.) CitationJ, Molina-Cerrillo, et al. "Toxicity-related Immunotherapy Discontinuation and Outcome in Patients with Advanced Renal Cell Carcinoma Treated with Immune-based Combinations (ARON-1 Study)." International Journal of Cancer 158, no. 5 (2026): 1396. https://doi.org/10.1002/ijc.70228.
MLA (9th ed.) CitationJ, Molina-Cerrillo, et al. "Toxicity-related Immunotherapy Discontinuation and Outcome in Patients with Advanced Renal Cell Carcinoma Treated with Immune-based Combinations (ARON-1 Study)." International Journal of Cancer, vol. 158, no. 5, 2026, p. 1396, https://doi.org/10.1002/ijc.70228.
